AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04101578 — intervention group
Intervention type: DRUG
Intervention: Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
Description: Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Study NCT02427750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aggripal®
Description: TIV
Study NCT00648661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets 20 mg
Description: 20mg, single dose fed
Study NCT00648661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lexapro® Tablets 20 mg
Description: 20mg, single dose fed
Study NCT00469157 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Optive
Description: Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
Study NCT05038579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Musiquence
Description: The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
Study NCT00392236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-way pager
Description: Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
Study NCT00392236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants will receive treatment as usual.
Study NCT03966248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chinese Tuina therapy
Description: 1. The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~2. The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~3. Massage the spleen and stomach meridians of the affected lower extremes;~4. Roll the soft tissues around the affected knee;~5. Relax the gastrocnalis muscle~6. The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~7. Push the patella and do the passive movement of the affected knee;~8. Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email.
Study NCT03966248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Manual therapy
Description: 1. Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~2. Activity training: Mainly about the knee joint flexion and extension movement training.~3. Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email.
Study NCT00846521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
Study NCT00333879 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Sound System
Description: Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
Study NCT01365117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Description: 15 subjects in a three-way crossover (three different doses of TI Inhalation Powder \[one 20 U, two 20 U and one 40 U cartridges)
Study NCT01365117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Description: 16 subjects in a four-way crossover (four different doses of TI Inhalation Powder \[one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)\])
Study NCT02756026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (Nutri-Fem)
Description: Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
Study NCT03899311 — intervention group
Intervention type: OTHER
Intervention: protein-sparing modified fast diet
Description: a PSMF diet follow the usual care format in the Center
Study NCT02747862 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP \[i.e. identifiable APC mutation\], and/or a compatible family history or personal adenoma burden of > 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016.
Study NCT03670264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Incentive
Description: The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
Study NCT03670264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Incentive
Description: The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
Study NCT03670264 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Way to Health (WTH) Platform
Description: The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
Study NCT03670264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Way to Health (WTH) Platform
Description: The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
Study NCT03670264 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Quitline Delivered Treatment
Description: The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
Study NCT03670264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Delivered Treatment
Description: The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
Study NCT01246011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban and warfarin
Description: Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
Study NCT02550730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birth Sisters Best Beginnings for Babies
Description: Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
Study NCT02550730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual maternity care
Description: Usual prenatal, intrapartum and postpartum maternity care
Study NCT03903926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5000 volunteers (6-35 months)-EV71 vaccine
Description: two doses EV71 vaccines will be administrated on day 0, 30 respectively
Study NCT03199430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epigallocatechin gallate
Study NCT03199430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1450mg Corn Flour
Study NCT01301586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline and S-equol
Description: Oral doxycycline and s-equol twice a day
Study NCT01301586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: ORAL DOXYCYCLINE TWICE A DAY
Study NCT02897687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Group
Description: A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
Study NCT02897687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book Club Group
Description: A topical book club group discussing Autism-related material conducted by a single healthcare professional.
Study NCT02345616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric oxide
Study NCT03072992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. solution, once weekly for 12 weeks
Study NCT00003834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00003834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00003834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00468052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
Study NCT00468052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: 1 microgram/kilogram as a bolus
Study NCT01864889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR vector-transduced T cells
Description: genetically engineered lymphocyte therapy
Study NCT03918967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-G11
Description: oral tablet of CT-G11 Experimental Drug
Study NCT03918967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-G20
Description: oral tablet of CT-G20 Experimental Drug
Study NCT03918967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CT-G11 Placebo
Description: oral tablet of Placebo
Study NCT03918967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CT-G20 Placebo
Description: oral tablet of Placebo
Study NCT03991754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter aortic valve implantation
Description: transcatheter aortic valve implantation
Study NCT03991754 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transcatheter aortic valve implantation
Description: transcatheter aortic valve implantation
Study NCT02530216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AEGIS (Automated Evaluation of Gastrointestinal Symptoms)
Description: AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint.
Study NCT03258268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care with EASY DSS
Description: The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone.
Study NCT03258268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care without EASY DSS
Description: Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone.
Study NCT05464043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: evaluation of second line glucose homeostasis
Description: blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
Study NCT00405886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane
Description: Oral tablets, duration: 16 weeks
Study NCT04476810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kahook dual blade
Description: Combined Phacoemulsification and Excisional Goniotomy with the Kahook Dual Blade
Study NCT03272087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy
Description: 50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
Study NCT00405886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets, duration: 16 weeks
Study NCT03449927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized menu
Description: -Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea
Study NCT03449927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care menu
Description: -Standard registered dietitian support
Study NCT03449927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self report dietary intake worksheet
Description: -Self report nausea and diarrhea
Study NCT03449927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self report dietary intake worksheet
Description: -Self report nausea and diarrhea
Study NCT03449927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post study questionnaire
Description: -Completed upon count recovery and prior to discharge
Study NCT03449927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post study questionnaire
Description: -Completed upon count recovery and prior to discharge
Study NCT01783249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stationary Exercise cycling
Description: Stationary exercise cycling
Study NCT02605356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Study NCT05247385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Compared platelet inhibition and adenosine levels at baseline and after 15 days
Study NCT05247385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Compared platelet inhibition and adenosine levels at baseline and after 15 days
Study NCT04804865 — intervention group
Intervention type: OTHER
Intervention: prognostic assessment
Description: determination of a prognostic score with 3 clinical and 5 biological parameters.
Study NCT03382314 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HDDO-1614
Description: * Combination drug (Bazedoxifene + Cholecalciferol)~* Incrementally modified drug~* Not market authorized product
Study NCT03382314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bazedoxifene / Cholecalciferol
Description: Co- Administration of Bazedoxifene and Cholecalciferol
Study NCT02788786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
Study NCT02788786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride
Description: non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
Study NCT02788786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salt and Water
Description: salt and water mix oral rinse
Study NCT03522610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
Study NCT02477163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ayurveda treatment
Description: 1. Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~2. Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~3. Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~4. Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~5. Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~6. Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch.
Study NCT04841460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-fat ground beef
Description: 5% fat ground beef
Study NCT04841460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat ground beef
Description: 25% fat ground beef
Study NCT03441724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mechanocardiography
Description: Mechanocardiographic recording
Study NCT02369900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Study NCT01201005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycobalamin
Description: Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
Study NCT01201005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: needle injection without any substance given
Study NCT04561830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision
Description: We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides.
Study NCT02313792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin
Study NCT01190345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
Study NCT01190345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no bevacizumab
Description: no bevacizumab
Study NCT04729868 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)
Description: evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries